Related Experiment Videos
Co-Amorphous Ursolic Acid-Quercetin Complex Improves Solubility and In Vivo Expectorant-Antitussive Activity
Yuhang Jiang1,2, Zehong Qiu1,2, Biaoshen Lin1,2
1College of Life Science, Longyan University, Longyan 364000, China.
Abstract:
This study investigated the formation of a co-amorphous complex between ursolic acid and quercetin as a chemically defined model system for improving the formulation performance of a poorly soluble triterpenoid acid. Co-amorphous systems were prepared by solvent evaporation and physical grinding at different mass ratios. The optimal formulations were identified and evaluated by water-solubility measurement, powder X-ray diffraction (PXRD), Fourier-transform infrared spectroscopy (FTIR), and in vivo expectorant-antitussive assays. The solvent-derived system showed higher water solubility than the ground system. PXRD and FTIR results suggested that the solvent method more effectively promoted loss of crystallinity and probable intermolecular interactions, whereas the grinding method largely retained the crystalline features of ursolic acid. Both ursolic acid-quercetin formulations exhibited enhanced expectorant and antitussive activities compared with pure ursolic acid. Although quercetin may contribute intrinsic pharmacological activity, the overall improvements were broadly consistent with the altered physicochemical properties of the co-amorphous systems, which may facilitate ursolic acid delivery. As a secondary exploratory comparison, plant-derived triterpenoid-acid-rich and flavonoid-rich fractions from Eriobotrya japonica leaves were also co-processed; however, because these fractions were not compositionally characterized, their results were interpreted cautiously and were not used as the primary basis for mechanistic conclusions. Overall, the present study demonstrates that co-amorphous complexation of ursolic acid and quercetin is a promising strategy for improving the solubility-related properties and in vivo activity of a poorly soluble triterpenoid acid.
Related Concept Videos
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Cholinergic Antagonists: Pharmacokinetics
Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Upper Respiratory Drugs: First and Second-Generation Antihistamines
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...